Has George Geils, MD received payments from drug or device companies?

Yes. Drug and device makers reported $930,183 in general payments to George Geils, MD across 934 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean George Geils, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about George Geils, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

George Geils, MD

Hematology & Oncology · Charleston, SCNPI 1093773657

Payments from drug & device makers

$930,183in general payments, 2019–2025

Across 934 payments — averaging $995.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Karyopharm Therapeutics Inc.$345K
AstraZeneca$212K
AbbVie$98K
Amgen$93K
Sanofi$56K
Sanofi US Services Inc.$42K
plus $84K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Karyopharm Therapeutics Inc.	16	$344,559
AstraZeneca(2 entities)	72	$212,184
AbbVie	24	$98,346
Amgen	73	$93,448
Sanofi	45	$55,525
Sanofi US Services Inc.	44	$41,890
Bristol Myers Squibb	32	$38,334
E.r. Squibb & Sons, L.L.C.	53	$23,036
Johnson & Johnson	51	$9,849
Beigene, Ltd.	2	$1,912
Merck	72	$1,446
Novartis	49	$878
Gilead(2 entities)	22	$670
Pfizer	40	$665
Mckesson Specialty Care Distribution, LLC	8	$589
Daiichi Sankyo Inc.	22	$541
Lilly USA, LLC	24	$521
Astellas Pharma US Inc	25	$519
Genentech USA, Inc.	24	$410
Seagen Inc.	19	$382
Jazz Pharmaceuticals Inc.	17	$332
Rigel Pharmaceuticals, Inc.	16	$322
Acrotech Biopharma Inc.	11	$270
Beigene USA, Inc.	11	$229
Bayer	13	$213
Takeda Pharmaceuticals U.S.A., Inc.	8	$196
Alnylam Pharmaceuticals Inc.	8	$188
Incyte Corporation	9	$177
Puma Biotechnology, Inc.	10	$174
AVEO Pharmaceuticals, Inc.	6	$151
Sobi, Inc	7	$141
Regeneron Healthcare Solutions, Inc.	6	$134
ADC Therapeutics America, Inc.	7	$126
GSK	5	$113
Array Biopharma Inc	7	$111
Pharmacyclics LLC, An Abbvie Company	6	$111
Tersera Therapeutics LLC	4	$107
Sanofi-aventis U.S. LLC	2	$107
Comsort, Inc	1	$100
Novocure Inc.	6	$84
Eisai Inc.	3	$71
Mirati Therapeutics, Inc.	3	$66
Exelixis Inc.	4	$66
Kyowa Kirin, Inc.	3	$59
Ipsen Biopharmaceuticals, Inc	3	$54
Taiho Oncology, Inc.	2	$52
G1 Therapeutics, Inc.	2	$46
Beone Medicines USA, Inc.	2	$44
Genmab U.S., Inc.	2	$44
EUSA Pharma (US) LLC	2	$42
Secura Bio, Inc.	3	$41
Stemline Therapeutics Inc.	1	$37
Servier Pharmaceuticals LLC	2	$32
Teva Pharmaceuticals USA, Inc.	2	$31
Boehringer Ingelheim	1	$28
Sumitomo Pharma America, Inc.	2	$28
Lexicon Pharmaceuticals, Inc.	2	$26
Blueprint Medicines Corporation	1	$26
Geron Corporation	1	$26
Aurobindo Pharma USA, Inc.	1	$24

How this compares

$930,183 in reported general payments places this provider in the 90th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$186,985

Medicare patients

176

Services billed

1,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Charleston

Robert StuartCharleston$2.9M
Brian LingerfeltCharleston$1.1M
James OrcuttCharleston$1.1M
John WrangleCharleston$919K
David EllisonCharleston$767K
George KeoghCharleston$745K
Russell JenkinsCharleston$627K
Irl GreenwellCharleston$376K
Ming LimCharleston$341K
Young LeeCharleston$338K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →